Treating and Managing Urinary Incontinence: Evolving and Potential Multicomponent Medical and Lifestyle Interventions

References

• Abrams P, Cardozo L, Wagg A, Wein A. Incontinence 6th Ed; 2017.
   Google Scholar
• Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87(9):760–766. doi:10.1046/j.1464-410x.2001.02228.x
   PubMed Web of Science ®Google Scholar
• Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108(7):1132–1138.
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int. 2006;97(1):96–100.
   PubMed Web of Science ®Google Scholar
• Swithinbank L, Hashim H, Abrams P. The effect of fluid intake on urinary symptoms in women. J Urol. 2005;174(1):187–189.
   PubMed Web of Science ®Google Scholar
• Hashim H, Abrams P. How should patients with an overactive bladder manipulate their fluid intake? BJU Int. 2008;102(1):62–66.
   PubMed Web of Science ®Google Scholar
• Cornu JN, Abrams P, Chapple CR, et al. A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management--a systematic review and meta-analysis. Eur Urol. 2012;62(5):877–890.
   PubMed Web of Science ®Google Scholar
• Alwis US, Delanghe J, Dossche L, et al. Could evening dietary protein intake play a role in nocturnal polyuria? J Clin Med. 2020;9(8):1.
   Web of Science ®Google Scholar
• Bozkurt YE, Temeltaş G, Müezzinoğlu T, Üçer O. Mediterranean diet and overactive bladder. Int Neurourol J. 2022;26(2):129–134.
   PubMed Web of Science ®Google Scholar
• Urinary incontinence and pelvic organ prolapse in women: management. NICE NG123; 2019.
   Google Scholar
• Andersson K-E. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004;3(1):46–53. doi:10.1016/S1474-4422(03)00622-7
   PubMed Web of Science ®Google Scholar
• Yeowell G, Smith P, Nazir J, Hakimi Z, Siddiqui E, Fatoye F. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open. 2018;8(11):e021889. doi:10.1136/bmjopen-2018-021889
   PubMed Web of Science ®Google Scholar
• Kouladjian O’Donnell L, Gnjidic D, Nahas R, Bell JS, Hilmer SN. Anticholinergic burden: considerations for older adults. J Pharm Pract Res. 2017;47(1):67–77. doi:10.1002/jppr.1303
   Google Scholar
• Song YS, Lee HY, Park JJ, Kim JH. Persistence and adherence of anticholinergics and beta-3 agonist for the treatment of overactive bladder: systematic review and meta-analysis, and network meta-analysis. J Urol. 2021;205(6):1595–1604. doi:10.1097/JU.0000000000001440
   PubMed Web of Science ®Google Scholar
• Igawa Y, Yamazaki Y, Takeda H, et al. Functional and molecular biological evidence for a possible β 3 -adrenoceptor in the human detrusor muscle. Br J Pharmacol. 1999;126(3):819–825. doi:10.1038/sj.bjp.0702358
   PubMed Web of Science ®Google Scholar
• NICE. Mirabegron for treating symptoms of overactive bladder. Technology appraisal guidance [TA290]; 2013.
   Google Scholar
• Kelleher C, Hakimi Z, Zur R, et al. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: a Systematic Review and Network Meta-analysis. Eur Urol. 2018;74(3):324–333. doi:10.1016/j.eururo.2018.03.020
   PubMed Web of Science ®Google Scholar
• Chapple CR, Nazir J, Hakimi Z, et al. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol. 2017;72(3):389–399. doi:10.1016/j.eururo.2017.01.037
   PubMed Web of Science ®Google Scholar
• Mo W, Michel MC, Lee XW, Kaumann AJ, Molenaar P. The β 3 -adrenoceptor agonist mirabegron increases human atrial force through β 1 -adrenoceptors: an indirect mechanism? Br J Pharmacol. 2017;174(16):2706–2715. doi:10.1111/bph.13897
   PubMed Web of Science ®Google Scholar
• Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T. Vibegron, a novel potent and selective β3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. Eur Urol. 2018;73(5):783–790. doi:10.1016/j.eururo.2017.12.022
   PubMed Web of Science ®Google Scholar
• Brucker BM, King J, Mudd PN Jr, McHale K. Selectivity and maximum response of vibegron and mirabegron for β3-adrenergic receptors. Curr Ther Res Clin Exp. 2022;96:100674. doi:10.1016/j.curtheres.2022.100674
   PubMed Web of Science ®Google Scholar
• Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol. 2020;204(2):316–324. doi:10.1097/JU.0000000000000807
   PubMed Web of Science ®Google Scholar
• Varano S, Staskin D, Frankel J, Shortino D, Jankowich R, Mudd PN Jr. Efficacy and safety of once-daily vibegron for treatment of overactive bladder in patients aged ≥65 and ≥75 years: subpopulation analysis from the EMPOWUR randomized, international, phase III study. Drugs Aging. 2021;38(2):137–146. doi:10.1007/s40266-020-00829-z
   PubMed Web of Science ®Google Scholar
• Kennelly MJ, Rhodes T, Girman CJ, Thomas E, Shortino D, Mudd PN Jr. Efficacy of vibegron and mirabegron for overactive bladder: a systematic literature review and indirect treatment comparison. Adv Ther. 2021;38(11):5452–5464.
   PubMed Web of Science ®Google Scholar
• Uckert S, Oelke M. Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. Br J Clin Pharmacol. 2011;72(2):197–204.
   PubMed Web of Science ®Google Scholar
• Chen H, Wang F, Yu Z, et al. Efficacy of daily low-dose tadalafil for treating overactive bladder: results of a randomized, double-blind, placebo-controlled trial. Urology. 2017;100:59–64.
   PubMed Web of Science ®Google Scholar
• Statement NP. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society; 2020.
   Google Scholar
• Robinson D, Cardozo L. Estrogens and the lower urinary tract. Neurourol Urodyn. 2011;30(5):754–757.
   PubMed Web of Science ®Google Scholar
• Cardozo L, Lose G, McClish D, Versi E. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scand. 2004;83(10):892–897.
   PubMed Web of Science ®Google Scholar
• Cold S, Cold F, Jensen MB, Cronin-Fenton D, Christiansen P, Ejlertsen B. Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study. J Natl Cancer Inst. 2022;114(10):1347–1354.
   PubMedGoogle Scholar
• Goldstein SR, Bachmann GA, Koninckx PR, Lin VH, Portman DJ, Ylikorkala O. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric. 2014;17(2):173–182.
   PubMed Web of Science ®Google Scholar
• Schiavi MC, Zullo MA, Faiano P, et al. Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms. Gynecol Endocrinol. 2017;33(12):942–945.
   PubMed Web of Science ®Google Scholar
• Novara L, Sgro LG, Mancarella M, Capece R, Canale E, Biglia N. Potential effectiveness of ospemifene on detrusor overactivity in patients with vaginal atrophy. Maturitas. 2020;138:58–61.
   PubMed Web of Science ®Google Scholar
• Matarazzo MG, Sarpietro G, Fiorito D, et al. Intravaginal 6.5 mg prasterone administration in postmenopausal women with overactive bladder syndrome: a pilot study. Eur J Obstet Gynecol Reprod Biol. 2021;263:67–71.
   PubMed Web of Science ®Google Scholar
• Burgen AS, Dickens F, Zatman LJ. The action of botulinum toxin on the neuro-muscular junction. J Physiol. 1949;109(1–2):10–24.
   PubMed Web of Science ®Google Scholar
• Fontaine C, Papworth E, Pascoe J, Hashim H. Update on the management of overactive bladder. Ther Adv Urol. 2021;13:17562872211039034.
   Web of Science ®Google Scholar
• Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol. 2007;177(6):2231–2236.
   PubMed Web of Science ®Google Scholar
• El-Hefnawy AS, Elbaset MA, Taha DE, et al. Trigonal-sparing versus trigonal-involved Botox injection for treatment of idiopathic overactive bladder: a randomized clinical trial. Low Urin Tract Symptoms. 2021;13(1):22–30.
   PubMed Web of Science ®Google Scholar
• Araklitis G, Cardozo L. Safety issues associated with using medication to treat overactive bladder. Expert Opin Drug Saf. 2017;16(11):1273–1280.
   PubMed Web of Science ®Google Scholar
• Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184(6):2416–2422.
   PubMed Web of Science ®Google Scholar
• Herschorn S, Kohan A, Aliotta P, et al. The efficacy and safety of OnabotulinumtoxinA or solifenacin compared with placebo in solifenacin naïve patients with refractory overactive bladder: results from a multicenter, randomized, double-blind phase 3b trial. J Urol. 2017;198(1):167–175.
   PubMed Web of Science ®Google Scholar
• Flint R, Rantell A, Cardozo L. AbobotulinumtoxinA for the treatment of overactive bladder. Expert Opin Biol Ther. 2018;18(10):1005–1013.
   PubMed Web of Science ®Google Scholar
• Bhide AA, Tailor V, Fernando R, Khullar V, Digesu GA. Posterior tibial nerve stimulation for overactive bladder-techniques and efficacy. Int Urogynecol J. 2020;31(5):865–870.
   PubMed Web of Science ®Google Scholar
• Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183(4):1438–1443.
   PubMed Web of Science ®Google Scholar
• Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, MacDiarmid SA. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. J Urol. 2013;189(6):2194–2201.
   PubMed Web of Science ®Google Scholar
• Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182(3):1055–1061.
   PubMed Web of Science ®Google Scholar
• Medical B. BlueWind RENOVA iStim™ for the treatment of Overactive Bladder (OAB); 2022. Available from: https://bluewindmedical.com/bluewind-renova/. Accessed June 12, 2023.
   Google Scholar
• van Breda HMK, Martens FMJ, Tromp J, Heesakkers J. A new implanted posterior tibial nerve stimulator for the treatment of overactive bladder syndrome: 3-month results of a novel therapy at a single center. J Urol. 2017;198(1):205–210.
   PubMed Web of Science ®Google Scholar
• Dorsthorst MJT, Digesu GA, Tailor V, et al. 3-year followup of a new implantable tibial nerve stimulator for the treatment of overactive bladder syndrome. J Urol. 2020;204(3):545–550.
   PubMed Web of Science ®Google Scholar
• Medtronics. InterStimTM II neurostimulator for bladder control and bowel control; 2022. Available from: https://www.medtronic.com/uk-en/healthcare-professionals/products/urology/sacral-neuromodulation-systems/interstim-ii.html. Accessed June 12, 2023.
   Google Scholar
• Axonics. Experience choice without compromise; 2022. Available from: https://www.axonics.com/hcp/axonics-system/system-overview. Accessed June 12, 2023.
   Google Scholar
• Siegel S, Noblett K, Mangel J, et al. Three-year follow-up results of a prospective, multicenter study in overactive bladder subjects treated with sacral neuromodulation. Urology. 2016;94:57–63.
   PubMed Web of Science ®Google Scholar
• Gandhi S, Gajewski JB, Koziarz A, Almutairi S, Ali A, Cox A. Long-term outcomes of sacral neuromodulation for lower urinary tract dysfunction: a 23-year experience. Neurourol Urodyn. 2021;40(1):461–469.
   PubMed Web of Science ®Google Scholar
• Pezzella A, McCrery R, Lane F, et al. Two-year outcomes of the ARTISAN-SNM study for the treatment of urinary urgency incontinence using the Axonics rechargeable sacral neuromodulation system. Neurourol Urodyn. 2021;40(2):714–721.
   PubMed Web of Science ®Google Scholar
• Krhut J, Peter L, Rejchrt M, Slovak M, Skugarevska B, Zvara P. Peroneal electric transcutaneous NeuroModulation (eTNM(®)): a novel method for the treatment of the overactive bladder. J Healthc Eng. 2021;2021:4016346.
   PubMed Web of Science ®Google Scholar
• Krhut J, Rejchrt M, Slovak M, et al. Prospective, randomized, multicenter trial of peroneal electrical transcutaneous neuromodulation vs solifenacin in treatment-naïve patients with overactive bladder. J Urol. 2023;209(4):734–741.
   PubMed Web of Science ®Google Scholar
• Rejchrt M, Krhut J, Gärtner M, Blok BFM, Zvara P. Effect duration of the initial course of peroneal electrical Transcutaneous NeuroModulation in patients with overactive bladder. World J Urol. 2023;2023:1.
   Google Scholar
• Holmquist ND, Bellina JH, Danos ML. Vaginal and cervical cytologic changes following laser treatment. Acta Cytol. 1976;20(4):290–294.
   PubMed Web of Science ®Google Scholar
• Robinson D, Flint R, Veit-Rubin N, Araklitis G, Cardozo L. Is there enough evidence to justify the use of laser and other thermal therapies in female lower urinary tract dysfunction? Report from the ICI-RS 2019. Neurourol Urodyn. 2020;39(Suppl 3):S140–s7.
   PubMed Web of Science ®Google Scholar
• Salvatore S, Leone Roberti Maggiore U, Athanasiou S, et al. Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex vivo study. Menopause. 2015;22(8):845–849.
   PubMed Web of Science ®Google Scholar
• Okui N. Efficacy and safety of non-ablative vaginal erbium:YAG laser treatment as a novel surgical treatment for overactive bladder syndrome: comparison with anticholinergics and β3-adrenoceptor agonists. World J Urol. 2019;37(11):2459–2466.
   PubMed Web of Science ®Google Scholar
• Perino A, Cucinella G, Gugliotta G, et al. Is vaginal fractional CO2 laser treatment effective in improving overactive bladder symptoms in post-menopausal patients Preliminary results? Eur Rev Med Pharmacol Sci. 2016;20(12):2491–2497.
   PubMed Web of Science ®Google Scholar
• Bosco N, Noti M. The aging gut microbiome and its impact on host immunity. Genes Immun. 2021;22(5–6):289–303.
   PubMed Web of Science ®Google Scholar
• Sze C, Pressler M, Lee JR, Chughtai B. The gut, vaginal, and urine microbiome in overactive bladder: a systematic review. Int Urogynecol J. 2022;33(5):1157–1164.
   PubMed Web of Science ®Google Scholar
• Pearce MM, Hilt EE, Rosenfeld AB, et al. The female urinary microbiome: a comparison of women with and without urgency urinary incontinence. mBio. 2014;5(4):e01283–14.
   PubMed Web of Science ®Google Scholar
• Li K, Chen C, Zeng J, et al. Interplay between bladder microbiota and overactive bladder symptom severity: a cross-sectional study. BMC Urol. 2022;22(1):39.
   PubMed Web of Science ®Google Scholar
• Okamoto T, Hatakeyama S, Imai A, et al. Altered gut microbiome associated with overactive bladder and daily urinary urgency. World J Urol. 2021;39(3):847–853.
   PubMed Web of Science ®Google Scholar
• Hamine S, Gerth-Guyette E, Faulx D, Green BB, Ginsburg AS. Impact of mHealth chronic disease management on treatment adherence and patient outcomes: a systematic review. J Med Internet Res. 2015;17(2):e52.
   PubMedGoogle Scholar
• Asklund I, Nyström E, Sjöström M, Umefjord G, Stenlund H, Samuelsson E. Mobile app for treatment of stress urinary incontinence: a randomized controlled trial. Neurourol Urodyn. 2017;36(5):1369–1376.
   PubMed Web of Science ®Google Scholar
• Hou Y, Feng S, Tong B, Lu S, Jin Y. Effect of pelvic floor muscle training using mobile health applications for stress urinary incontinence in women: a systematic review. BMC Womens Health. 2022;22(1):400.
   PubMed Web of Science ®Google Scholar
• Cardozo L, Drutz HP, Baygani SK, Bump RC. Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstet Gynecol. 2004;104(3):511–519.
   PubMed Web of Science ®Google Scholar
• Cardozo L, Lange R, Voss S, et al. Short- and long-term efficacy and safety of duloxetine in women with predominant stress urinary incontinence. Curr Med Res Opin. 2010;26(2):253–261.
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Haab F, Robinson D. A randomized, placebo-controlled clinical development program exploring the use of litoxetine for treating urinary incontinence. Neurourol Urodyn. 2021;40(6):1515–1523.
   PubMed Web of Science ®Google Scholar
• Galloway NT, El-Galley RE, Sand PK, Appell RA, Russell HW, Carlan SJ. Extracorporeal magnetic innervation therapy for stress urinary incontinence. Urology. 1999;53(6):1108–1111.
   PubMed Web of Science ®Google Scholar
• Weber-Rajek M, Strączyńska A, Strojek K, et al. Assessment of the Effectiveness of Pelvic Floor Muscle Training (PFMT) and Extracorporeal Magnetic Innervation (ExMI) in treatment of stress urinary incontinence in women: a randomized controlled trial. Biomed Res Int. 2020;2020:1019872.
   PubMed Web of Science ®Google Scholar
• Braga A, Castronovo F, Caccia G, et al. Efficacy of 3 tesla functional magnetic stimulation for the treatment of female urinary incontinence. J Clin Med. 2022;11(10):1.
   Web of Science ®Google Scholar
• Chermansky CJ, Tarin T, Kwon DD, et al. Intraurethral muscle-derived cell injections increase leak point pressure in a rat model of intrinsic sphincter deficiency. Urology. 2004;63(4):780–785.
   PubMed Web of Science ®Google Scholar
• Hart ML, Izeta A, Herrera-Imbroda B, Amend B, Brinchmann JE. Cell Therapy for Stress Urinary Incontinence. Tissue Eng Part B Rev. 2015;21(4):365–376.
   PubMed Web of Science ®Google Scholar
• Kuismanen K, Sartoneva R, Haimi S, et al. Autologous adipose stem cells in treatment of female stress urinary incontinence: results of a pilot study. Stem Cells Transl Med. 2014;3(8):936–941.
   PubMed Web of Science ®Google Scholar
• Arjmand B, Safavi M, Heidari R, et al. Concomitant transurethral and transvaginal-periurethral injection of autologous adipose derived stem cells for treatment of female stress urinary incontinence: a phase one clinical trial. Acta Med Iran. 2017;55(6):368–374.
   PubMedGoogle Scholar
• Sèbe P, Doucet C, Cornu JN, et al. Intrasphincteric injections of autologous muscular cells in women with refractory stress urinary incontinence: a prospective study. Int Urogynecol J. 2011;22(2):183–189.
   PubMed Web of Science ®Google Scholar
• Peters KM, Dmochowski RR, Carr LK, et al. Autologous muscle derived cells for treatment of stress urinary incontinence in women. J Urol. 2014;192(2):469–476.
   PubMed Web of Science ®Google Scholar
• Blaganje M, Šćepanović D, Žgur L, Verdenik I, Pajk F, Lukanović A. Non-ablative Er:YAG laser therapy effect on stress urinary incontinence related to quality of life and sexual function: a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2018;224:153–158.
   PubMed Web of Science ®Google Scholar
• Okui N. Comparison between erbium-doped yttrium aluminum garnet laser therapy and sling procedures in the treatment of stress and mixed urinary incontinence. World J Urol. 2019;37(5):885–889.
   PubMed Web of Science ®Google Scholar
• Lauterbach R, Aharoni S, Justman N, Farago N, Gruenwald I, Lowenstein L. The efficacy and safety of a single maintenance laser treatment for stress urinary incontinence: a double-blinded randomized controlled trial. Int Urogynecol J. 2022;33(12):3499–3504.
   PubMed Web of Science ®Google Scholar
• Millheiser LS, Pauls RN, Herbst SJ, Chen BH. Radiofrequency treatment of vaginal laxity after vaginal delivery: nonsurgical vaginal tightening. J Sex Med. 2010;7(9):3088–3095.
   PubMed Web of Science ®Google Scholar
• Leibaschoff G, Izasa PG, Cardona JL, Miklos JR, Moore RD. Transcutaneous Temperature Controlled Radiofrequency (TTCRF) for the treatment of menopausal vaginal/genitourinary symptoms. Surg Technol Int. 2016;29:149–159.
   PubMedGoogle Scholar
• Seki AS, Bianchi-Ferraro A, Fonseca ESM, Sartori MGF, Girão M, Jarmy-Di Bella ZIK. CO(2) Laser and radiofrequency compared to a sham control group in treatment of stress urinary incontinence (LARF study arm 3). A randomized controlled trial. Int Urogynecol J. 2022;33(12):3535–3542.
   PubMed Web of Science ®Google Scholar
• Paget LDA, Reurink G, de Vos RJ, et al. Effect of platelet-rich plasma injections vs placebo on ankle symptoms and function in patients with ankle osteoarthritis: a randomized clinical trial. JAMA. 2021;326(16):1595–1605.
   PubMed Web of Science ®Google Scholar
• Andia I, Rubio-Azpeitia E, Martin JI, Abate M. Current concepts and translational uses of platelet rich plasma biotechnology; 2015.
   Google Scholar
• Chiang CH, Kuo HC. The efficacy and mid-term durability of urethral sphincter injections of platelet-rich plasma in treatment of female stress urinary incontinence. Front Pharmacol. 2022;13:847520.
   PubMed Web of Science ®Google Scholar
• Athanasiou S, Kalantzis C, Zacharakis D, Kathopoulis N, Pontikaki A, Grigoriadis T. The use of platelet-rich plasma as a novel nonsurgical treatment of the female stress urinary incontinence: a prospective pilot study. Female Pelvic Med Reconstr Surg. 2021;27(11):e668–e72.
   PubMed Web of Science ®Google Scholar